Back to Startup Insights
Ascidian Therapeutics
RNA exon editing company rewriting RNA to treat disease, inspired by sea squirts (ascidians); its platform replaces mutated exons in RNA transcripts, offering gene-therapy durability without DNA-editing risks.
Headquarters
Boston, USA
Year Founded
2022
Founders
Romesh Subramanian (founding CEO), Apple Tree Partners
Country
United States
Financial Information
Funding Stage
Series A
Recent Funding
$90M
Funding By
Apple Tree Partners, Lilly (collaboration)
Core Technology
RNA exon editing (trans-splicing)
Product Type
Drug
Pipeline Stage (Very Important)
Phase I/II (ACDN-01 for Stargardt disease)
Regulatory Status
- IND Filed: Yes
- FDA/EMA Status: FDA Clinical
- Clinical Trial Registration: ACDN-01 Phase I/II (Stargardt disease)
- Patents / IP Status: Filed
Partnerships
Pharma Collaborations
Eli Lilly (up to $1.9B renal disease collaboration)
Academic / Hospital Tie-ups
Apple Tree Partners ecosystem
CRO/CDMO Partnerships
Forge Biologics (manufacturing)
Market & Differentiation
RNA exon editing replaces multiple exons at once, avoiding DNA editing risks